

COMPETITIVE TECHNOLOGIES

(thousands, except per share amounts)

| INCOME STATEMENT | FY2011 | | | 5 Mos. Ended December 31, 2010* | FY 2010 | | | | | FY 2009 |
|------------------------------------|-----------------|-------------------|-----------------|---------------------------------------|-------------------|-----------------|-----------------|-----------------|-----------------|-------------------|
| | Q3 | Q2 | Q1 | | Year | Q4 | Q3 | Q2 | Q1 | Year |
| Product Sales | \$ 1,198 | \$ 311 | \$ 1,827 | \$ 164 | \$ 1,854 | \$ 1,049 | \$ 518 | \$ 152 | \$ 135 | \$ 8 |
| Cost of Product Sales | \$ (505) | \$ (122) | \$ (857) | \$ (28) | \$ (516) | \$ (399) | \$ (108) | \$ (9) | \$ - | \$ (1) |
| Gross Revenues | \$ 693 | \$ 189 | \$ 970 | \$ 136 | \$ 1,338 | \$ 650 | \$ 410 | \$ 143 | \$ 135 | \$ 7 |
| Gain on Sale of Rental Assets | - | - | 35 | - | 81 | - | - | 81 | - | - |
| Retained Royalties | 4 | 5 | 12 | 12 | 68 | 17 | 13 | 29 | 9 | 261 |
| Interest and Other Income | 9 | 10 | 12 | 12 | 7 | - | - | 6 | (1) | 79 |
| Total Revenues | \$ 706 | \$ 204 | \$ 1,029 | \$ 160 | \$ 1,494 | \$ 667 | \$ 423 | \$ 259 | \$ 143 | \$ 347 |
| Selling Expenses | 219 | 96 | 101 | - | - | - | - | - | - | - |
| Personnel & Consulting | 431 | 406 | 367 | 660 | 2,061 | 521 | 588 | 510 | 442 | 2,024 |
| General & Admin. | 601 | 997 | 517 | 1,169 | 2,134 | 615 | 572 | 491 | 456 | 2,198 |
| Restructuring Expense | - | - | - | 326 | - | - | - | - | - | - |
| Bad Debt Expense | - | - | - | 409 | - | - | - | - | - | - |
| Unrealized loss on derivative | (15) | 30 | 3 | - | - | - | - | - | - | - |
| Insurance Recovery | - | - | - | - | - | - | - | - | - | (400) |
| Interest Expense | 9 | 10 | 10 | 4 | 7 | 1 | 2 | 3 | 1 | 3 |
| Total Expenses | \$ 1,245 | \$ 1,539 | \$ 998 | \$ 2,568 | \$ 4,202 | \$ 1,137 | \$ 1,162 | \$ 1,004 | \$ 899 | \$ 3,825 |
| Income (loss) before taxes | \$ (538) | \$ (1,335) | \$ 29 | \$ (2,408) | \$ (2,709) | \$ (468) | \$ (739) | \$ (745) | \$ (756) | \$ (3,480) |
| (Benefit) Provision for taxes | - | - | - | - | - | - | - | - | - | - |
| Net Income (Loss) | \$ (538) | \$ (1,335) | \$ 29 | \$ (2,408) | \$ (2,709) | \$ (468) | \$ (739) | \$ (745) | \$ (756) | \$ (3,480) |
| Preferred Stock Dividend | - | - | - | (132) | - | - | - | - | - | - |
| Net Income (Loss) to Common | \$ (538) | \$ (1,335) | \$ 29 | \$ (2,540) | \$ (2,709) | \$ (468) | \$ (739) | \$ (745) | \$ (756) | \$ (3,480) |
| Basic \$/share | \$ - | \$ - | \$ - | \$ (0.18) | \$ (0.25) | \$ (0.04) | \$ (0.07) | \$ (0.07) | \$ (0.08) | \$ (0.40) |
| Basic Shares | 14,255 | 13,747 | 13,826 | 13,825 | 10,832 | 11,867 | 11,057 | 10,526 | 9,885 | 8,740 |
| Fully Diluted \$/share | \$ - | \$ - | \$ - | \$ (0.18) | \$ (0.25) | \$ (0.04) | \$ (0.07) | \$ (0.07) | \$ (0.08) | \$ (0.40) |
| Fully Diluted Shares | 14,255 | 13,747 | 14,467 | 13,825 | 10,832 | 11,867 | 11,057 | 10,526 | 9,885 | 8,740 |

*The Company has changed its year-end reporting period from July 31 to December 31.

Number of Calmare Devices

sold in each period

| | | | | | | | | | |
|---------------------|----|---|----|---|-----|----|----|---|----|
| Domestic Sales | 20 | 4 | 8 | 3 | 12 | 4 | 2 | 5 | 1 |
| International Sales | 2 | 2 | 63 | 0 | 114 | 60 | 41 | 2 | 11 |
| Total Sales | 22 | 6 | 71 | 3 | 126 | 64 | 43 | 7 | 12 |